BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update

(NASDAQ:BHST) (FSE:8MV0) BioHarvest Sciences Inc reported financial results for the three and nine months ended September 30, 2026, and outlined its strategic priorities for 2027. Q3 2026 revenue was $7.9 million, down from $8.8 million in Q2 2026 and $9.1 million in Q3 2025, reflecting a deliberate moderation of lower-return customer acquisition in the Products Business Unit and the timing of CDMO development revenue. Gross margin for Q3 2026 was 54%, compared to 58% in Q2 2026 and approximately 61% in Q3 2025, due to a revenue mix weighted toward Products and a lower contribution from higher-margin CDMO development revenue. Operating loss was $3 million, compared with $2.5 million in Q2 2026 and $0.9 million in Q3 2025. Cash, cash equivalents and bank deposits totaled $12.5 million at September 30, 2026, versus $16.2 million at June 30, 2026 and $23 million at December 31, 2025. The company is focusing on cash preservation, controlled VINIA growth, and concentrating CDMO resources on select programs with the clearest commercial and manufacturing pathways. In August, BioHarvest signed the CDMO division's first manufacturing and supply agreement, an exclusive agreement covering the scaled production of a rare, high-value, plant-based fragrance ingredient, with a UAE-based customer. The agreement provides for the production of an anticipated 20 tons of the fragrance composition, with limited production potentially beginning as early as Q1 2027. In September, BioHarvest launched single-dose VINIA Daily Chews to broaden consumer choice and provide an additional pathway for customer acquisition and revenue growth. Cost of revenue for Q3 2026 was $3.6 million, compared to $3.5 million for the same period last year. Gross profit in Q3 2026 was $4.2 million, or 54% of total revenue, compared to $5.6 million, or 61% of total revenue, in Q3 2025. R&D expenses totaled $1.8 million for Q3 2026, compared to $1.4 million for Q3 2025, primarily due to higher technology development expenditures within the CDMO Services Business Unit. Sales and marketing expenses were $4.0 million for Q3 2026, compared to $4.1 million for Q3 2025. G&A expenses were $1.5 million for Q3 2026, compared to $0.9 million for Q3 2025, with the increase primarily reflecting one-time income of $0.4 million recognized in Q3 2025. Net loss for Q3 2026 was $3.3 million, or $0.15 per basic and diluted share, compared to a net loss of $2.5 million, or $0.14 per basic and diluted share, for Q3 2025. Adjusted EBITDA loss was $2.0 million, compared to $0.4 million in Q3 2025. Under the two-lens approach, Q3 2026 Adjusted EBITDA losses of the CDMO services and Products divisions were $1.4 million and $0.6 million respectively, compared to $0.2 million and $0.2 million in Q3 2025. Full-year revenue guidance for the VINIA D2C business has been revised to $31-$32 million, while Adjusted EBITDA loss guidance remains unchanged at $1.5-$2.5 million. The 20-ton plant-based fragrance supply agreement is estimated to generate revenue of $20-$30 million in 2027-2028. The CDMO business has revised its expected full-year revenue range to $1-$1.5 million and now anticipates a full-year Adjusted EBITDA loss of $4-$5 million. On a consolidated basis, the company now expects full-year 2026 revenue of $32-$33.5 million and an Adjusted EBITDA loss in the range of $5.5-$7.5 million. The company will hold its Q3 2026 earnings call on November 12, 2026 at 8:00 a.m. Eastern Time.

BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

(NASDAQ: BHST) BioHarvest Sciences Inc announced results from the second quarter and six months of 2026, reporting $8.8 million in Q2 revenue, up 3.8% from Q2 2025. The company secured its first ever CDMO Manufacturing Agreement supporting a planned 20-ton commercial production program over two years for a rare botanical fragrance. Gross margins for the three months ended June 30, 2026 were 58% of revenue compared to 59% for the same period last year. Total operating loss for the three months ended June 30, 2026 was $2.5 million compared to $1.8 million for the same period last year. Net loss for the three months ended June 30, 2026 was $3.7 million compared to $4.1 million for the same period last year. BioHarvest was awarded a $1.4M Grant from the Israel Innovation Authority (IIA) in July to support predictive AI and manufacturing scale-up. The company revised full-year 2026 guidance, tightening the CDMO business expected revenue range to $4-$5 million and reducing expected full-year EBITDA loss to $1.5m - $2.5 million.

BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance

(NASDAQ: BHST) BioHarvest Sciences Inc announced an exclusive manufacturing and supply agreement through 2027 and 2028 that is estimated to generate $20-$30 million in revenue. The agreement secures production of a rare, endangered, fragrance plant cell culture with an undisclosed customer based in the United Arab Emirates. BioHarvest will serve as the exclusive manufacturing partner for its proprietary unique fragrance cell culture composition and will reserve manufacturing capacity to support the anticipated commercial requirements. BioHarvest will prepare to start limited production in the first half of 2027, with planned production volumes totaling 20 metric tons of a product with specifications to be finalized over the next few months. The agreement anticipates that, contingent upon delivery of the product, BioHarvest could recognize between $20-$30 million in revenue at the time of completion. BioHarvest has a 20% ownership stake in this developed composition. The premium fragrance segment is estimated to represent a $23B market opportunity within the global $58.9B scents and fragrances industry.

BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis

(NASDAQ: BHST) BioHarvest Sciences Inc announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing into its biological development workflows. The grant is the second received from the IIA this year, with the first dedicated to scaling the manufacturing facility by integrating industrial automation and machine learning on the factory floor. The new initiative focuses on transforming early-stage R&D through predictive AI and aims to maximize active metabolite yields. The grant was provided as a non-dilutive, zero-interest loan, with repayment contingent upon the achievement of certain predefined commercial milestones and expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant. The company cautions there is no assurance that future revenues will be generated from the project or that any developed molecule or compound will be commercialized.

Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation

BioHarvest Sciences Inc. (NASDAQ: BHST) announced the expansion of its collaboration with Tate & Lyle PLC to broaden their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an initial agreement signed in 2024 and leverages BioHarvest's Botanical Synthesis™ platform for developing non-GMO, plant-based ingredients. Tate & Lyle's approach aims to provide food and beverage manufacturers with a flexible toolkit of sweetening solutions, supporting sugar and calorie reduction goals. The announcement highlights strong technical progress, consumer demand for plant-based sweeteners, and the companies' commitment to ingredient innovation. BioHarvest's platform has achieved commercial validation through its flagship product VINIA®, with nearly $100 million in cumulative sales. Tate & Lyle recently acquired CP Kelco, enhancing its solutions capabilities, and reported pro forma revenue of £2.12 billion for the year ended 31 March 2025. Forward-looking statements caution that there is no assurance of future contracts or commercialization success.

BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

BioHarvest Sciences Inc. (NASDAQ: BHST) reported its first quarter 2026 financial results, with total revenues of $8.5 million, representing an 8% year-over-year increase. The company achieved significant milestones in its CDMO fragrance and Saffron projects, advancing two major Botanical Synthesis programs into Stage 2 development with combined agreements valued at over $2 million. The VINIA brand customer base grew to 90,000 active users as of the end of April, and the VINIA Blood Flow Hydration product achieved $920,000 in cumulative revenue since its launch in November 2025. Operating loss for the quarter was $1.8 million, and net loss was $2.6 million. Cash and cash equivalents as of March 31, 2026, totaled $20.2 million.

BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division

BioHarvest Sciences Inc. (NASDAQ: BHST) announced the appointment of Nedira Salzman-Frenkel as Vice President of Business Development. Ms. Salzman-Frenkel will focus on sourcing and managing new contracts for BioHarvest's contract development and manufacturing organization (CDMO) business, targeting pharmaceutical, nutraceutical, nutrition, and cosmetic sectors. She brings over a decade of experience in the life sciences industry, including securing approximately $30 million dollars in CRO contracts. The company is preparing for anticipated growth and the launch of a new facility next year. This appointment is aligned with BioHarvest's strategy to build long-term partnerships and expand its Botanical Synthesis platform.

BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications

BioHarvest Sciences Inc. (NASDAQ: BHST) announced that its CDMO division has completed Stage 1 of a multi-stage development agreement valued at $1.125 million, establishing a stable saffron cell bank for potential nutraceutical and culinary applications. The agreement with SaffronTech advances to Stage 2, focusing on generating enough biomass for pre-commercial testing and product development. BioHarvest holds a 25% ownership position in the saffron composition and will earn manufacturing royalties from future production. Saffron is described as one of the world's most valuable botanicals, with prices ranging from approximately $3,000 to more than $10,000 per kilogram and a 2025 global market estimated at nearly $500 million.

BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform

BioHarvest Sciences Inc. (NASDAQ: BHST) announced that its CDMO division has signed a $1.2 million-dollar Stage 2 contract as part of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. The contract follows the successful completion of Stage 1 in March 2026, where a stable cell bank of a unique cell culture-based composition was produced. At the end of Stage 2, which will take approximately six to nine months, BioHarvest will have produced enough of the fragrance raw material for commercial trials. BioHarvest retains 20% ownership of the compositions developed and will earn a second source of revenue as the manufacturing entity, aiming for a long-term, royalty-driven economic model. The premium fragrance segment is estimated to represent a $23 billion-dollar market opportunity within the global $58.9 billion scents and fragrances industry.